NCT06879067View on ClinicalTrials.gov

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

July 23, 2019

Study Completion Date

November 9, 2020

Conditions
SafetyTolerability
Interventions
DRUG

Placebo

Placebo nasal spray

DRUG

Foralumab Nasal

foralumab nasal spray

Trial Locations (1)

02115

Ann Romney Center for Neurologic Diseases, Boston

All Listed Sponsors
lead

Tiziana Life Sciences LTD

INDUSTRY

NCT06879067 - Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers | Biotech Hunter | Biotech Hunter